Philip Hewitt
Merck KGaA
28 Papers
123 Citations
Philip Hewitt is an academic researcher from Merck KGaA. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 12, co-authored 20 publications.
Chat about Author
Papers
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
Patricio Godoy,Nicola J. Hewitt,Ute Albrecht,Melvin E. Andersen,Nariman Ansari,Sudin Bhattacharya,Johannes G. Bode,Jennifer Bolleyn,Christoph Borner,J Böttger,Albert Braeuning,Robert A. Budinsky,Britta Burkhardt,Neil R. Cameron,Giovanni Camussi,Chong Su Cho,Yun Jaie Choi,J. Craig Rowlands,Uta Dahmen,Georg Damm,Olaf Dirsch,María Teresa Donato,Jian Dong,Steven Dooley,Dirk Drasdo,Dirk Drasdo,Dirk Drasdo,Rowena Eakins,Karine Sá Ferreira,Valentina Fonsato,Joanna Fraczek,Rolf Gebhardt,Andrew Gibson,Matthias Glanemann,Christopher E. Goldring,María José Gómez-Lechón,Geny M. M. Groothuis,Lena Gustavsson,Christelle Guyot,David Hallifax,Seddik Hammad,Adam S. Hayward,Dieter Häussinger,Claus Hellerbrand,Philip Hewitt,Stefan Hoehme,Hermann-Georg Holzhütter,J. Brian Houston,Jens Hrach,Kiyomi Ito,Hartmut Jaeschke,Verena Keitel,Jens M. Kelm,B. Kevin Park,Claus Kordes,Gerd A. Kullak-Ublick,Edward L. LeCluyse,Peng Lu,Jennifer Luebke-Wheeler,Anna Lutz,Daniel J. Maltman,Madlen Matz-Soja,Patrick D. McMullen,Irmgard Merfort,Simon Messner,Christoph Meyer,Jessica Mwinyi,Dean J. Naisbitt,Andreas K. Nussler,Peter Olinga,Francesco Pampaloni,Jingbo Pi,Linda J. Pluta,Stefan Przyborski,Anup Ramachandran,Vera Rogiers,Cliff Rowe,Celine Schelcher,Kathrin Schmich,Michael Schwarz,Bijay Singh,Ernst H. K. Stelzer,Bruno Stieger,Regina Stöber,Yuichi Sugiyama,Ciro Tetta,Wolfgang E. Thasler,Tamara Vanhaecke,Mathieu Vinken,Thomas S. Weiss,Agata Widera,Courtney G. Woods,Jinghai James Xu,Kathy Yarborough,Jan G. Hengstler +94 more
TL;DR: This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro and how closely hepatoma, stem cell and iPS cell–derived hepatocyte-like-cells resemble real hepatocytes.
Human???Induced Pluripotent Stem Cells Generate Light Responsive Retinal Organoids with Variable and Nutrient???Dependent Efficiency
Dean Hallam,Gerrit Hilgen,Birthe Dorgau,Lili Zhu,Min Yu,Sanja Bojic,Philip Hewitt,Michael Schmitt,Marianne Uteng,Stefan Kustermann,David H. W. Steel,Mike Nicholds,Robert Thomas,Achim Treumann,Andrew Porter,Evelyne Sernagor,Lyle Armstrong,Majlinda Lako +17 more
TL;DR: The data indicate that light responsive retinal organoids derived from carefully selected and differentiation efficient iPSC lines can be generated at the scale needed for pharmacology and drug screening purposes.
186
Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity
Dana Hoffmann,Tobias C. Fuchs,Tanja Henzler,Katja Matheis,Thomas Herget,Wolfgang Dekant,Philip Hewitt,Angela Mally +7 more
TL;DR: Altered urinary excretion of KIM-1, clusterin, calbindin and Timp-1 accompanied by a rise in BUN was observed in rats with BI-3 at 1000 mg/kg bw for 14 days.
176
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
Andreas Baudy,Monicah A. Otieno,Philip Hewitt,Jinping Gan,Adrian Roth,Douglas A. Keller,Radhakrishna Sura,Terry R. Van Vleet,William R Proctor +8 more
TL;DR: This guidance on best approaches to benchmark liver MPS based on 3 stages of characterization that includes key performance metrics and a 20 compound safety test set is provided.
113
The evolving role of investigative toxicology in the pharmaceutical industry
Francois Pognan,Mario Beilmann,H. C. M. Boonen,Andreas Czich,Gordon Dear,Philip Hewitt,Tomas Mow,Teija Oinonen,Adrian Roth,Thomas Steger-Hartmann,Jean-Pierre Valentin,Freddy Van Goethem,Richard J. Weaver,Peter Newham +13 more
TL;DR: In this article , the authors provide an overview of the current status of the field using case studies and discuss the potential impact of ongoing technological developments, based on a survey of investigative toxicologists from 14 European-based medium-sized to large pharmaceutical companies.